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Immune checkpoint molecules function as a system of checks and balances that
enhance or inhibit immune responses to infectious agents, foreign tissues, and cancerous cells. Immunotherapies that target immune checkpoint molecules, particularly the
inhibitory molecules programmed cell death 1 and cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4), have revolutionized human oncology in recent years, yet little is
known about these key immune signaling molecules in species other than primates
and rodents. The Tasmanian devil facial tumor disease is caused by transmissible
cancers that have resulted in a massive decline in the wild Tasmanian devil population. We have recently demonstrated that the inhibitory checkpoint molecule PD-L1 is
upregulated on Tasmanian devil (Sarcophilus harrisii) facial tumor cells in response to
the interferon-gamma cytokine. As this could play a role in immune evasion by tumor
cells, we performed a thorough comparative analysis of checkpoint molecule protein
sequences among Tasmanian devils and eight other species. We report that many of
the key signaling motifs and ligand-binding sites in the checkpoint molecules are highly
conserved across the estimated 162 million years of evolution since the last common
ancestor of placental and non-placental mammals. Specifically, we discovered that the
CTLA-4 (MYPPPY) ligand-binding motif and the CTLA-4 (GVYVKM) inhibitory domain
are completely conserved across all nine species used in our comparative analysis,
suggesting that the function of CTLA-4 is likely conserved in these species. We also
found that cysteine residues for intra- and intermolecular disulfide bonds were also
highly conserved. For instance, all 20 cysteine residues involved in disulfide bonds
in the human 4-1BB molecule were also present in devil 4-1BB. Although many key
sequences were conserved, we have also identified immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs) in
genes and protein domains that have not been previously reported in any species.
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This checkpoint molecule analysis and review of salient features for each of
the molecules presented here can serve as road map for the development of a
Tasmanian devil facial tumor disease immunotherapy. Finally, the strategies can
be used as a guide for veterinarians, ecologists, and other researchers willing to
venture into the nascent field of wild immunology.
Keywords: devil, transmissible tumor, cosignaling immunotherapy, checkpoint blockade, wild immunity,
allograft, transplant rejection, evolution

by which anti-CTLA-4 works are not completely understood.
Accumulating evidence suggests that anti-CTLA-4 works primarily in the secondary lymphoid organs by releasing pre-existing
T cells from inhibitory signaling to target tumor neoantigens and
by depleting Tregs in the tumor microenvironment (10, 11).
Despite the promising early results of anti-CTLA-4 mAb
monotherapy in human clinical trials, objective response rates
remained low in most cases. Improvements have been observed
when anti-CTLA-4 was paired with other treatments, such as the
chemotherapy drug dacarbazine (12). However, the most promising outcomes have been observed when anti-CTLA-4 mAb is
paired with blockade of the programmed cell death 1 (PDCD1,
PD-1) protein (13–15).
Anti-PD-1 has been the most successful checkpoint blocking
monoclonal antibody in treating human cancer, in monotherapies or in combination therapies. Anti-CTLA-4 and anti-PD-1
combination therapies have achieved unprecedented objective
response rates of nearly 60% in patients with stage III and IV
melanoma (14, 15). PD-1 immunotherapies have focused largely
on stimulating T cell antitumor responses by blocking binding of
PD-1 to its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC,
CD273). PD-1 blockade abrogates the inhibitory effects of PD-1
ligation mediated by the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch
motif (ITSM) in the PD-1 cytoplasmic tail (16–18). In addition
to blocking the inhibitory effects of PD-1, blockade of PD-L1
ligation can render tumor cells less resistant to apoptosis (19).
PD-L1 and PD-L2 proteins are largely absent in normal tissues,
but PD-L1 expression is elevated in more than 20 types of human
cancer [reviewed in Ref. (20)]. Furthermore, many cancers and
healthy cells upregulate PD-L1 expression in response to inflammatory cytokines, such as interferon-gamma (IFN-γ).
In humans, PD-L1 expression in the tumor microenvironment
is associated with an inhibited T cell antitumor response and
reduced patient survival [reviewed in Ref. (20)]. PD-L1 expression in the tumor microenvironment plays an important role in
shaping a dysfunctional immune response through reprogramming of APCs, regulatory T cells, and expression of inhibitory
molecules. PD-L2 is not routinely detected on cancer cells, but
is commonly expressed by DCs, which led to the alternative
name of B7-DC (21). A second coreceptor for PD-L2, repulsive
guidance molecule b, has recently been discovered and has been
implicated in respiratory immune tolerance (22).
Orthologs of CTLA-4 and PD-1 and their coreceptors have
been found in nearly all mammals and birds studied to date
(23, 24), but comparatively little is known about the potential for
checkpoint molecule immunotherapy in the field of veterinary

INTRODUCTION
The immune system plays a vital role in protecting an animal from
pathogens and cancers through various immunosurveillance and
effector mechanisms. The pathogenic cells and/or microbes that
escape or neutralize host immunity produce more surviving
descendants that are in turn more effective at evading immune
responses. The architecture of the vertebrate immune system and
the mechanisms by which immune responses are regulated are
the result of this long and complex evolutionary arms race. This
arms race drives continuous evolution of the immune system, but
many defenses have persisted throughout this long-history and
are conserved across speciation events.
Immune checkpoint molecules function as a complex system
of checks and balances that promote or inhibit immune responses.
Checkpoint molecules likely evolved to precisely balance the need
to control pathogens and cancer with the need to maintain tolerance to healthy tissues and the microbiota (Figure 1). However,
the delicate balance of tolerance and immunity can be upset by
pathogens and tumor cells that subvert inhibitory pathways to
evade host immune defenses.
Checkpoint molecule immunotherapy has recently surged
onto the world stage, but this field emerged over three decades of
basic immunobiological research, primarily focused on T cells.
In general, activation of T cells requires signaling through the
T cell receptor (TCR) (signal 1) and cosignaling through CD28
(signal 2), a constitutively expressed disulfide-linked homodimer
on the surface of naïve T cells (1–3). Signal one is derived from
interactions of the TCR with its cognate major histocompatibility
complex (MHC) peptide-complex (4). Signal two is derived from
CD28 binding with either CD80 (B7-1) or CD86 (B7-2), primarily
expressed by dendritic cells (DCs) and other antigen-presenting
cells (APCs), such as macrophages and B cells. TCR signaling in
the absence of CD28 cosignaling can result in T cell anergy (5).
Following activation of T cells, the inhibitory molecule cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) is upregulated on
the cell surface (6). CTLA-4 has a higher affinity for both CD80
and CD86 than does CD28 (7–9), and thus CD28 cosignaling is
suppressed by CTLA-4 outcompeting CD28 for CD80 and CD86
binding. The result is a downregulation of the T cell response and
loss of T cell function.
Immunotherapies targeting the CTLA-4 checkpoint molecule
have opened new doors in the realm of human oncology. Two
antagonistic anti-CTLA-4 mAbs, ipilimumab (IgG1 isotype) and
tremelimumab (IgG2 isotype), that block interactions between
CTLA-4 and its coreceptors CD80 and CD86 have been clinically
approved for advanced stage cancers. The exact mechanisms
Frontiers in Immunology | www.frontiersin.org
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Figure 1 | Generalized schematic of checkpoint molecule structure and expression, and the balance between stimulatory and inhibitory signaling.
(A) The net balance of inhibitory (−, blue) and stimulatory (+, red) signals regulates antitumor immune responses. The tumor microenvironment is dynamic and is
molded by inhibitory and stimulatory signals both in the microenvironment and distant tissues (i.e., lymph nodes). Development of cytotoxic effector T cells and
NK cells is regulated by the balance between inhibitory and stimulatory signaling, including both receptor:coreceptor interactions and cytokines. Both receptor and
cytokine expression are also regulated by that balance of stimulatory and inhibitory signals, creating feedback loops that evolved to eliminate pathogens and cancer
while simultaneously limiting collateral damage. (B) Expanded view of potential receptor:coreceptor interactions between T cells, NK cells, antigen-presenting cells
(APCs), and tumor cells. The graphic here demonstrates some of the best characterized pathways, with a particular focus on T cell and NK cell interactions with
tumor cells and APCs. Note that many of the ligands depicted here are expressed on several cell types and interactions with coreceptors and ligands can result in
different functional outcomes depending on the cell types and microenvironment. For example, CD47 is expressed on all cells, but the pathway of primary interest
for transmissible tumors is for the ability of tumor cell-expressed CD47 to inhibit phagocytosis via binding to SIRP-α on APCs. In addition to binding to SIRP-α,
CD47 also binds to SIRP-β, SIRP-γ, THBS1, and THBS2, but we have only shown the CD47:SIRP-α interaction here to keep the figure relatively simple. Both
V-domain Ig suppressor of T cell activation (VISTA) and B7-H4 have unknown coreceptors (labeled as “?” in the diagram) whose function has been studied
using fusion proteins, but the genes for the coreceptors have yet to be identified.

medicine or in the realm of wildlife disease. Initial investigations
into the function of CTLA-4, PD-1, and PD-L1 have been undertaken for canids (25–30), felids (31), and bovids (32–35), and
results suggest that the CTLA-4 and PD-1/PD-L1 expression patterns and function are similar among these placental mammals.
An area where checkpoint molecule immunology could make
a wildlife conservation impact is in the unusual cases of transmissible tumors. These transmissible tumors represent a unique
immunological enigma because they can also simultaneously be
considered infections and allografts. Disease progression, transmission, and the host immune response can only be properly
understood when these tumors are considered in this complex
tumor–infection–allograft context.
The Tasmanian devil facial tumor (DFT) was identified in
1996, and in 2006 the etiologic agent was found to be cancer
cells that are transmitted between biting devils (36, 37). At the
time of discovery, the only other known naturally transmissible tumors were the canine (Canis lupus familiaris) transmissible venereal tumor (38, 39) and a set of related Syrian hamster
(Mesocricetus auratus) transmissible sarcomas (40, 41). In recent
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years, additional transmissible tumors have been discovered in
soft-shell clams and other bivalves (42, 43). Remarkably, in
2015, we discovered a second transmissible devil facial tumor
(DFT2) in wild Tasmanian devils (referred to as devils hereafter)
that is genetically distinct from the original devil facial tumor
(DFT1) (44).
Previous research has shown that reduced cell surface expression of MHC-I plays a major role in DFT1 immune evasion, but
that IFN-γ can upregulate beta-2 microglobulin (β2m), ergo
MHC-I expression (45). This immune evasion mechanism has
been described in many types of cancer, and begs the question as
to why the MHC-negative DFT cells are not targeted by NK cells
in line with the “missing-self ” hypothesis (46). Studies have demonstrated the NK cell genes are present in devils and that devil
NK-like cells can mount an antitumor response (47–49). Despite
the complimentary mechanisms of cytotoxic T cells and NK cells,
immune responses against the DFTs are rare (50), suggesting that
additional immune evasion mechanisms could be present.
Recent vaccination efforts have demonstrated that IFNγ-stimulated DFT cells can induce antitumor responses and
3
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Sequences

tumor regressions in a subset of cases (51). However, initial
forays into checkpoint molecule immunology of the DFT
disease has shown that both DFT1 and DFT2 also upregulate
PD-L1 upon exposure to IFN-γ (52), suggesting that anti-DFT
immunotherapies could be enhanced by neutralizing the PD-1
inhibitory pathway. Given that the immune system has many
redundant mechanisms for identifying and killing infectious
agents and tumors, it is likely that the transmissible tumors
employ additional methods beyond MHC-I downregulation
and PD-L1 upregulation for evading host immune defenses and
facilitating tumor transmission.
We have performed a comparative analysis of the protein
sequences of key immune checkpoint molecules in the three
mammalian species known to harbor naturally transmissible
cancers (devils, dogs, and hamsters) and six other mammals
(Table 1). We have not included the analysis of PD-1, PD-L1,
and PD-L2 here, as we have previously published this information (52). Understanding the broad role of checkpoint molecules
in these complex diseases has the potential to shed light on
fundamental aspects of immune evasion, transplant tolerance
and rejection, and infectious disease; this is logically relevant to
both human and veterinary medicine. This checkpoint molecule
analysis and review of salient features for each of the molecules
presented here can serve as road map for the development of a
DFT immunotherapy and as a guide for veterinarians, ecologists,
and other researchers willing to venture into the nascent field of
wild immunology.

DNA sequences for all genes analyzed here were collected from
GenBank and Ensembl and reference numbers for all sequences
are available in Table S1 in Supplementary Material (53). All
reference sequences current as of 30-Jan-2017, including the
most current devil genome (Devil_ref v7.0). The complete
coding sequence for the V-domain Ig suppressor of T cell activation (VISTA), CD47, and TIM-3 genes was not available from
either GenBank or Ensembl, so sequences were obtained from
a de novo transcriptome assembly (Table S2 in Supplementary
Material) described below. The full coding sequences were submitted to GenBank with accession numbers: KY856749 (VISTA),
KY856750 (CD47), and KY856751 (TIM-3). Where more than
one sequence was present we generally chose GenBank transcript
X1, unless preliminary alignments suggested that an alternative
transcript was a better match to the other species used here.
BLAST was used to find additional potential matching sequences
for each gene (54). The available reference sequences for several
genes that have not been characterized in their respective species
contained elongated 5′ regions upstream of the likely start codon,
so we manually truncated the amino acid sequences depicted in
the alignment figures for the following genes: opossum CD80 and
VISTA, bat CD86 and CD47, and hamster B7-H4.

RNA Sequencing (RNA-seq)

RNA sequencing data were generated as part of a previous
study (55). Briefly, RNA was extracted from peripheral blood
mononuclear cells (PBMCs) obtained from two disease-free
devils. Illumina single-end 100 bp RNA-seq was conducted by
the Australian Genome Research Facility. Sequencing generated
82,609,965 and 82,254,904 sequences, respectively. Fastq reads
for each sample were assessed with FastQC version 0.11.5 (56),
with both samples having acceptable per base sequence quality
measurements. Genome-independent de novo assembly of the
RNA-seq data was completed using the Trinity platform version 2.2.0 (57, 58) with default settings applied. This generated
a reference transcriptome of assembled transcripts collectively
from the two samples. The de novo transcriptome assembly was
queried with BLASTN version 2.4.0+ (59) with coding sequences
of the target genes obtained from Ensembl (53), database version
87.7, and UCSC Genome Browser (60). This identified transcript
sequences from the assembled transcriptome of our target genes
to use in comparative alignment analysis. Further information
on this analysis is detailed in the Data Sheet S1 in Supplementary
Material. Access to the raw fastq sequence data, Trinity assembled
de novo transcriptome, and BLASTN results are detailed in the
Data Sheet S1 in Supplementary Material.

MATERIALS AND METHODS
Species

We included nine species in our comparative analysis of checkpoint molecules. Humans and mice were included because
checkpoint molecules have been best characterized in these
species. We have included the little brown bat (Myotis lucifugus)
in our comparative analyses because like devils, the species has
recently undergone a dramatic population crash due to disease,
and understanding bat immunology has become increasingly
important due to the ability of bats to serve as reservoirs for
viral pathogens (e.g., rabies, ebola, SARS). We have also included
cats (Felis catus) and cattle (Bos taurus) due to their widespread
distribution as important domestic animals. See Table 1 for a full
list of species names and abbreviations used.

Table 1 | Names and identifiers for species used in comparative
sequence analysis.
#

Short name

Common name

Species name

Taxid

1
2
3
4
5
6
7
8
9

Devil
Opossum
Bat
Cat
Cattle
Dog
Hamster
Human
Mouse

Tasmanian devil
Gray short-tailed opossum
Little brown bat
Domestic cat
Cattle
Domestic dog
Golden hamster
Human
House mouse

Sarcophilus harrisii
Monodelphis domestica
Myotis lucifugus
Felis catus
Bos taurus
Canis familiaris
Mesocricetus auratus
Homo sapiens
Mus musculus

9305
13616
59463
9685
9913
9615
10036
9606
10090

Frontiers in Immunology | www.frontiersin.org

Protein Sequence Alignments

Protein sequences were aligned with CLC sequence viewer
using a progressive alignment algorithm with gap open cost = 5,
gap extension cost = 1, end gap cost = free (61, 62). Pairwise
protein sequence identities between devils and other species
were determined using the default parameters on the Clustal
Omega web server (63). We used the RasMol coloring scheme
to highlight traditional amino acid properties in all sequence

4
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alignments, which aids in interpretation of amino differences
across species (64).

used to confirm predicted signal peptides (69). Disulfide bonds
and other unique features of each protein that were annotated
on UniProt (70) were used to predict features in devil protein
sequences.

Analysis of Protein Sequences

All sequences were analyzed using the ExPASy server ProtParam
tool to predict molecular weight and extinction coefficients (65).
The eukaryotic linear motif (ELM) tool was used to predict key
signaling motifs (66). The Simple Modular Architecture Research
Tool (SMART) and the Phobius web server (67) were used to predict Ig-like domains and membrane topology (68). SignalP was

RESULTS
The CTLA-4 and CD28 pathways are perhaps the most studied
of the checkpoint molecules, but functional testing in species
other than mice and humans is limited. A battery of tools (i.e.,

Figure 2 | Alignment of cytotoxic T-lymphocyte-associated protein 4 reference genes for nine species. The predicted signal peptides (SigP), extracellular
domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide
bonds. MYPPPY indicates the conserved CD80- and CD86-binding site. GVYVKM indicates a conserved cytoplasmic inhibitory domain and TRAF indicates a
putative TRAF6-binding site. The black bars graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino
acid sequence identity between devils and other species is shown in the bottom right corner of the alignment.
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Table 2 | Protein sequence percent identity between checkpoint molecules in devils and eight other species.
Species

Cytotoxic T-lymphocyteassociated protein 4

CD28

CD80

CD86

V-domain Ig
suppressor of
T cell activation

4-1BB

CD47

SIRP-α

CD200

TIM-3

Lymphocyte
activation
gene 3

B7-H4

Opossum
Bat
Cat
Cattle
Dog
Hamster
Human
Mouse

85.7
68.5
68.9
66.1
68.9
65.3
65.8
63.1

72.4
53.9
55.9
56.0
56.4
57.4
56.2
54.4

55.2
33.9
36.9
36.3
35.0
33.6
35.5
35.7

49.2
35.9
35.1
35.9
37.8
32.4
36.6
35.0

73.7
65.6
64.8
65.8
63.2
60.0
64.9
61.9

75.5
48.0
51.2
50.8
53.8
43.4
52.2
44.2

87.1
54.2
65.2
67.4
67.1
64.2
66.8
64.5

69.2
56.3
56.6
55.3
56.7
52.7
55.8
53.1

65.7
54.7
56.3
53.2
52.8
51.7
56.2
53.2

52.7
43.0
43.3
42.1
43.1
44.4
43.2
42.3

72.5
48.7
46.3
50.6
43.0
48.7
51.9
50.0

93.9
84.1
85.9
85.9
87.7
79.6
87.0
81.9

Percent identity was calculated by Clustal 2.1 algorithm.

recombinant proteins, monoclonal antibodies) and time are
needed for proper testing of checkpoint molecule function, but
much information and insight into function can be gained by
analysis of protein sequences. For each molecule analyzed, we
begin with a description of the general structure (i.e., Ig-like
superfamily domains) and proceed to more nuanced details. This
provides insight into potential functions of the molecules and can
provide direction for designing critical experiments prior to the
embarking on the time-consuming process of empirical testing of
molecular function. See Table S3 in Supplementary Material for
details of checkpoint molecule structure.

here, only cattle CD28 did not contain the CD28MYPPPY motif (71);
cattle had a CD28LYPPPY sequence, which matches the CD28LYPPPY
and CTLA-4LYPPPY that has been previously reported in pigs (Sus
scrofa) and decreases affinity of porcine CTLA-4 for human
CD80 and CD86 (35, 72). Additionally, all species also contain
the CTLAGVYVKM inhibitory domain. Except for bats, all species
also contain the key CD28SDYMNM and CD28PYAP motifs are critical
for intracellular signaling that promotes T cell proliferation and
survival via the CD28–PI3K–AKT [reviewed in Ref. (73)]. Bats
have a CD28M228L substitution in the CD28SDYMNM motif.

CTLA-4, CD28, CD80, and CD86

The two marsupials examined contain a putative TRAF6-binding
domain in CTLA-4 proteins that was not present in any of the
placental mammals. We identified a putative ITIM in predicted
the ECD of dog CD80VKYGDL and a TRAF1/2-binding site in the
devil CD80ATEEE cytoplasmic domain (Figure 4). Our analysis
predicted a TRAF6-binding site in the cytoplasmic tail of devil
CD86GHPKERDEV, a motif not predicted for CD86 in other species
(Figure 5). Interestingly, the ELM tool predicted a putative ITIM
domain in the second Ig-like segment of the human CD86IEYDGI
ECD. To our knowledge, this putative ITIM has not been previously reported, and thus the potential inhibitory capacity of this
motif is unknown.

Potential Unique Signaling Motifs Identified

Devil CTLA-4 and CD28 are predicted to be 25 and 28 kDa,
respectively, type-I transmembrane proteins with a single Ig-like
V-type extracellular domain (ECD) (Figure 1). Protein sequence
identity for CTLA-4 between devils and opossums was 86% and
ranged from 63 to 69% between devils and placental mammals
(Figure 2; Table 2). Percent identity for CD28 among species
was lower than for CTLA-4, with 72% between devils and opossums and ranging from 54 to 57% between devils and placental
mammals (Figure 3). Devil CTLA-4 had approximately 29%
amino acid sequence identity with CD28. The CTLA-4 and CD28
coreceptors CD80 and CD86 are predicted to both be 35 kDa
type-I transmembrane proteins that contain Ig-like V-type and
an Ig-like C2-type domains. Devil CD80 and CD86 share only
21% sequence identity with each other, and the identity across
the species analyzed here ranges from 34 to 55% and 32–49%
for CD80 (Figure 4; Table 2) and CD86 (Figure 5; Table 2),
respectively; the percent identity for CD80 and CD86 across species is the lowest of any of the checkpoint molecules compared
here. All intra- and intermolecular disulfide bonds that have been
identified in humans for CTLA-4, CD28, CD80, and CD86 are
likely present in all the orthologs analyzed here, as we observed
100% conservation of cysteine residues at these sites in all species
tested (Figures 2–5).

V-Domain Ig Suppressor of T Cell
Activation

Devil VISTA (PD-1H, C10orf54, Gi24, DD1α, Dies1) is a type-I
transmembrane protein in the Ig superfamily predicted to be
33 kDa. The full coding sequence for this gene was previously
not available in the devil genome (Devil_ref v7.0), but our de
novo RNA transcriptome assembly uncovered a full coding devil
VISTA transcript. Devil VISTA shares 60–74% sequence identity
at the protein level with the other species analyzed here (Figure 6;
Table 2). The ELM tool predicted a TRAF1/2-binding site in the
ECD of devil VISTASIQE.

Key Ligand-Binding Regions Conserved in Devil
CTLA-4 and CD28

4-1BB

Our analysis shows that devil CTLA-4 and CD28 both contain
the MYPPPY motif that is necessary for binding of CTLA-4 and
CD28 to CD80 and CD86 in humans and mice (Figures 2 and 3)
(7). Of the 18 combined CTLA-4 and CD28 sequences aligned

Frontiers in Immunology | www.frontiersin.org

4-1BB (TNFRSF9, CD137) is a predicted 31 kDa member of the
tumor necrosis factor (TNF) receptor family expressed predominantly as a type-I transmembrane homodimer (74, 75). 4-1BB
ligand (4-1BBL, TNFSF9, CD137L) is a TNF family member
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Figure 3 | Alignment of CD28 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. MYPPPY indicates the conserved
CD80- and CD86-binding site, and SDYMNM and PYAP indicate key phosphorylation sites involved with cell proliferation and activation. The black bar graphs
below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species
is shown in the bottom right corner of the alignment.
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Figure 4 | Alignment of CD80 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. The uppermost devil CD80 sequence is the full-length sequence and the lower devil CD80 is the
potential secreted CD80 sequence. “d” above the alignment represents predicted disulfide bonds. TRAF indicates a putative TRAF1/2-binding site. The black bar
graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other
species is shown in the bottom right corner of the alignment.
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Figure 5 | Alignment of CD86 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. TRAF indicates a putative TRAF6binding site. The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity
between devils and other species is shown in the bottom right corner of the alignment. See Table 2 for the sequence identity between devils and other species.
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Figure 6 | Alignment of V-domain Ig suppressor of T cell activation reference genes for nine species. The predicted signal peptides (SigP), extracellular
domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide
bonds and “TRAF” indicates a potential TRAF1/2-binding site. The black bar graphs below the alignment represent the conservation of amino acids across all nine
species. The percent amino acid sequence identity between devils and other species is shown in the bottom right corner of the alignment.
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of 20 kDa, expressed as a type II transmembrane homotrimer
(Figure 1). SMART analysis of devil 4-1BB identified two
TNFR-Cys repeat domains, whereas human 4-1BB contains four
TNFR-Cys repeats (Figure 7). All cysteine repeats in the four
human TNFR-Cys domains were conserved in devils, suggesting
that devil 4-1BB might also contain four TNFR-Cys domains
despite not being predicted by the SMART program. Indeed, all
20 cysteine residues involved in disulfide bonds in human 4-1BB
were also present in devil 4-1BB. Overall sequence identity among
species compared here ranged from 43 to 75%, with mouse and
hamster 4-1BB having the lowest percent identities with devil
4-1BB (Table 2).
We identified a putative inhibitory domain in devil 4-1BBLPYFLK
based on alignment with a potential inhibitory domain in human
4-1BBLLYIFK (76, 77). The putative inhibitory domain resembles
an ITIM domain but lacks the I, L, or V in the terminal amino
acid position. To date, this potential inhibitory domain has only
been reported in humans, but several species analyzed here have
similar motifs. Additionally, mice have a 4-1BBCXCP motif in the
cytoplasmic domain that facilitates binding of CD4 and CD8
molecules to p56lck, a protein tyrosine kinase that is important
for optimal T cell responses (78, 79); of the nine species compared
here, mice are the only species that have the 4-1BBCXCP sequence.
Our analysis using the ELM tool predicted two TRAF1/2 ligandbinding sites (devil 4-1BBTAQEE, 4-1BBPEEE), which align with the
known TRAF1/2-binding sites in human and mouse 4-1BB (80).

are conserved in devils (Figure S1 in Supplementary Material).
The percent sequence identity for SIRP-α ranged from 53 to
69%. Analysis of devil SIRP-α revealed two putative ITIM and
one ITSM domain. The ITIMITYADL shares 100% identity with
all species except cattle, and the ITIMLTYADL is 100% conserved
across all species. The devil ITSMSQTEYASI matches 5/7 amino
acids with all other species; to our knowledge no ITSM has
previously been reported in SIRP-α. We identified two potential SIRP-β1 orthologs in devils (ENSSHAT00000016950,
XM_012553634.1) that contained ITIM motifs (SIRP-β1VSYNLI)
in the ECD. The putative SIRP-β1 (ENSSHAT00000016950)
ITIM aligned with an SIRP-β1VSYNIT sequence in SIRP-α that
contains the key tyrosine residue for ITIMs but did not contain
the canonical 3′ I/V/L.

CD200

Devil CD200 is predicted to be a 31 kDa type-I transmembrane
protein that shares 52–66% sequence identity across the species compared here (Figure 9; Table 2). The cysteine residues
that form intramolecular and intermolecular disulfide bonds
necessary for binding as either a monomer or homodimer to
CD200 receptor (CD200R) are 100% conserved across all species
examined here (Figure 9) (85). Additionally, the Ig-like V-type
and Ig-like C2-type domains of human and mouse CD200 were
identified by the SMART tool. Many key motifs, including endocytic sorting signals, and TRAF2, SH2, and SH3 binding motifs,
are present in all species compared here. Our analysis using ELM
predicts a potential ITSM only in devil CD200. However, the
devil CD200TLQE TRAF1/2-binding site and CD200NKTEYVVI ITSM
are both located in the predicted ECD of devil CD200, so empirical testing is needed to determine if these are functional sites.
Although not analyzed in depth here, CD200R and CD200R-like
proteins were identified in the nine species compared here. The
primary reference sequence for each species contained the key
CD200RNPLY motif (86), which has been shown to be a key motif
for CD200R inhibitory function (87).

CD47

Human CD47, also known as integrin-associated protein for
its role in cell adhesion, is a cell surface protein that contains
five transmembrane segments and a single Ig-like V-type
domain (81, 82). The most up-to-date gene sequences for devil
CD47 in Ensembl (ENSSHAT00000014546.1) did not contain
a full coding sequence (i.e., no start codon) and the GenBank
(XM_012544496) gene had an extended 5′ region that did not
align well with other species. Our de novo RNA transcriptome
assembly uncovered a full coding transcript for CD47 from devil
PBMCs that aligned well with other species analyzed here. Our
analysis suggests that the 34 kDa devil CD47 also contains five
transmembrane segments and a single Ig-like domain (Figure 8).
The four cysteines needed for the disulfide bonds reported in
human CD47 are conserved in all species examined here, and
overall sequence identity across all species compared here ranges
from 54 to 87% (Table 2). Curiously, the ELM tool predicted
an ITIM in the devil CD47LKYHVV ECD. All other species except
bats and hamsters also contain the putative ITIM domains,
but the ELM tool classified the ITIM as an excluded motif due
to the putative ITIM being located in ECD of the protein. We
also identified a putative TRAF2-binding site in the third devil
intracellular domain of CD47KAVEE that was conserved across all
species examined here except bats.

TIM-3

TIM-3, also known as T-cell immunoglobulin and mucin
domain-containing protein 3, hepatitis A virus cellular receptor 2, and CD366, is a surface protein expressed on T cells,
Tregs, monocytes, macrophages, and DCs in mice and humans
[reviewed in Ref. (88)]. The most up-to-date gene sequences
for devil TIM-3 in Ensembl (ENSSHAT00000018107.1) and
GenBank (XM_012552117.1) had truncated 3′ region of the
coding sequence, and the Ensembl gene had an extended 5′
region that did not align with other species. Our de novo RNA
transcriptome assembly uncovered a full coding devil TIM-3
transcript from devil PBMCs that aligned well with other species
analyzed here. Analysis of the devil TIM-3 predicted sequence
suggests that it is a 24 kDa protein with a Ig-like V-type domain
and mucin domain in the extracellular region of the protein
(Figure 10). Percent amino acid sequence identity between
devils and the other eight species analyzed here ranges from 42
to 53%, which is the lowest identity for any molecule analyzed
here except for CD80 and CD86 (Table 2). Despite this relatively
low conservation of protein sequence, many of the key TIM-3

SIRP-α

Devil SIRP-α is a predicted 56 kDa protein. Human SIRP-α
binds to CD47 as either a monomer or a dimer (83, 84) and
forms three intramolecular disulfide bonds. All six of the
cysteines that form intramolecular disulfide bonds in humans
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Figure 7 | Alignment of 4-1BB reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. Two potential TRAF1/2-binding sites
are demarcated by “TRAF.” “CXCP” marks a motif associated with optimal T cell response in mice, and “LPYFLK” denotes a potential inhibitory domain in devils.
The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between
devils and other species is shown in the bottom right corner of the alignment.
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Figure 8 | Alignment of CD47 reference genes for nine species. The predicted signal peptides (SigP), extracellular domains (ECDs), transmembrane domains
(TMDs), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential
TRAF1/2-binding site and immunoreceptor tyrosine-based inhibitory motif (ITIM) marks a putative ITIM motif predicted in the ECD. The black bar graphs below the
alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species is shown
in the bottom right corner of the alignment.
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Figure 9 | Alignment of CD200 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential
TRAF1/2-binding site and “ITSM” represents a putative immunoreceptor tyrosine-based switch motif (ITSM). The black bar graphs below the alignment represent
the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species is shown in the bottom right
corner of the alignment.
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Figure 10 | Alignment of TIM-3 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential
TRAF1/2-binding site and “MILIBS” demarcates a conserved metal ion-dependent ligand-binding site (MILIBS) found in phosphatidylserine on the surface of
apoptotic cells. The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence
identity between devils and other species is shown in the bottom right corner of the alignment.
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DISCUSSION

features identified in mice and humans appear to be present in
devil TIM-3.
A unique feature of human TIM-3 is the double cleft which
facilitates binding to multiple ligands (89, 90). The six cysteines
that form three intramolecular disulfide bonds in the Ig-like region
of human TIM-3 (89) are all present in devil TIM-3 (Figure 10),
suggesting that devil TIM-3 folding and structure might be similar
to human TIM-3. Analysis of human TIM-3 sequences identified
five key amino acids for the two ligand-binding clefts; four of the
five key amino acids were conserved in devil TIM-3. All species
analyzed here also have two critical tyrosine residues in the
TIM-3 cytoplasmic domain that align with mouse TIM-3Y256 and
TIM-3Y263 (Figure 10), which are phosphorylated following ligation by GAL-9 and are associated with increased NFAT/AP-1 and
NF-κB activity (91). A TIM-3TIEE TRAF1/2-binding site is located
between these tyrosine residues in all species except for cats, dogs,
and cattle (Figure 10). Also, mouse TIM-1, TIM-3, and TIM-4 all
bind to phosphatidylserine on the surface of apoptotic cells via
a conserved metal ion-dependent ligand-binding site (MILIBS).
The mouse TIM-3RIQFPGLMND MILIBS motif is 100% conserved in
cats, dogs, and cattle TIM-3, whereas devils have a phenylalanine
instead of a methionine in this motif. Whether this TIM-3M114F
affects phosphatidylserine binding and clearance of apoptotic
cells in devils is unknown.

Evolutionary Conservation of Key Protein
Regions

Despite an estimated 162 million years of evolution since the
last common ancestor of placental and non-placental mammals,
most of the checkpoint molecules we analyzed have orthologs in
Tasmanian devils. Importantly, many of the key signaling motifs
and ligand-binding sites are highly conserved in the genes analyzed, particularly cysteine residues for intra- and intermolecular
disulfide bonds and transmembrane and intracellular tyrosine
residues for receptor tyrosine kinases. The strong conservation of
the key protein regions suggests that inhibitory and stimulatory
function of these molecules, which is relatively well-documented
in humans and mice, is conserved in devils. Importantly, by following established procedures and focusing on the checkpoint
molecules that have proven most clinically effective in humans,
we can rapidly characterize key checkpoint molecules in devils
and incorporate potent immunomodulatory agents into our DFT
disease vaccine-development efforts.

The Web of CD28–CTLA-4 Cosignaling
Pathways

Our analysis shows for the first time that the key CTLA-4MYPPPY
and CD28MYPPPY are conserved in devils. Given that the MYPPPY
motif present in chickens facilitates binding to mammalian
CD80 and that a single leucine for methionine substitution in pig
CTLA-4LYPPPY is sufficient to disrupt binding of porcine CTLA-4
to human CD80 (35, 72, 96), the evolutionary conservation of
CTLA-4MYPPPY and CD28MYPPPY in devils suggests that the competitive binding of CTLA-4 and CD28 for CD80/86 should be
present in devils.
In addition to the conserved binding motifs, the key
CD28SDYMNN stimulatory domain (97) and CTLAGVYVKM inhibitory domains are also conserved in devils, suggesting that the
complementary stimulatory and inhibitory functions of CD28
and CTLA-4 are present. The CTLA-4GVYVKM motif, in association
with T-cell receptor-interacting molecule (TRIM), regulates surface expression of CTLA-4 (98). The TRIM-mediated recycling
of CTLA-4 from the surface provides the means for cell-extrinsic
inhibitory function by trans-endocytosis of CD80/86 (99). By
trans-endocytosing, or in other words stripping CD80/86 from
the surface of an opposing cell (i.e., APCs) and degrading the
CD80/86 molecules in the CTLA-4-expressing cell, the potential
of costimulation via CD80/86 binding to CD28 is eliminated.
Whether trans-endocytosis or trogocytosis (100) occurs in
devils is unknown. It could be readily tested by developing
CD80 transgenic cell lines that have a fluorescent protein,
such as green fluorescent protein (GFP), fused to the 3′ tail of
CD80. Flow cytometric or immunofluorescence observations
of GFP transferred from the transgenic cell line to the CTLA-4
expressing cells would demonstrate that this inhibitory pathway
is conserved in devils.
The complex interactions involving CTLA-4 are further complicated by some anti-CTLA-4 monoclonal antibody effects that
are mediated through Fc receptor signaling (11, 101, 102). Tregs

Lymphocyte Activation Gene 3

In humans and mice, LAG-3 (CD223) is an inhibitory type-I
transmembrane protein that is structurally homologous to
CD4 (92). Human and mice LAG-3 each contain one Ig-like
V-type and three Ig-like C-type domains, whereas devil LAG-3
is predicted to be a 54 kDa protein with three Ig-like domains.
However, a 100 amino acid (LAG3330–429) region downstream of
the three predicted Ig-like domains could contain a fourth Ig-like
domain that was not predicted by the SMART prediction tool
(68, 93). Devil LAG-3 percent sequence identity with the other
eight species analyzed here ranges from 43 to 73% (Table 2). In
humans and mice, the LAG-3KIEELE (Figure S2 in Supplementary
Material) motif in the cytoplasmic domain is critical for downstream inhibitory signaling interactions, but this exact sequence
is not present in the other species analyzed here. The critical
lysine (LAG-3K468) in this motif is present in devil (LAG-3KAEEME)
and all other mammals tested here, with the exception of opossums (LAG-3IAEQME).

B7-H4

Devil V-set domain-containing T-cell activation inhibitor 1,
or more commonly referred to as B7 homolog 4 (B7-H4), is a
30 kDa type-I membrane protein that contains two Ig-like
V-type domains in the extracellular region (Figure 11). Devil
B7-H4 protein shares 87% sequence identity with human B7-H4
and ranges from 80 to 94% for the other seven species analyzed
here (Table 2). Based on homology to human and mouse B7-H4
and analysis of devil B7-H4 using cNLS Mapper (score of 3.4)
(94, 95), it is likely that devil B7-H4KKRGH contains a bipartite
nuclear localization signal (NLS). Interestingly, B7-H4 has only
two amino acids in the cytoplasmic domain when expressed as
a surface protein.
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Figure 11 | Alignment of V-set domain-containing T-cell activation inhibitor 1 reference genes for nine species. The predicted signal peptides (SigP),
extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted
disulfide bonds. NLS indicates a predicted nuclear localization signal. The black bar graphs below the alignment represent the conservation of amino acids across all
nine species. The percent amino acid sequence identity between devils and other species is show in the bottom right corner of the alignment.

expressing high levels of CTLA-4 can be killed via antibodydependent cell-mediated cytotoxicity, thus reducing the inhibition of antitumor immunity. This could be a useful tactic for
increasing T cell responses against neoantigens in DFT cells, but
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To our knowledge only a single IgG subclass has been identified
in marsupials (103), and the number and type of Fc receptors
are unknown. Investigations into devil isotypes and Fc receptors
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are needed to aid development of potential monoclonal antibody
immunotherapies for devils. Additionally, we identified a potential TRAF1/2-binding site in devil CD80 and a TRAF6-binding
site in devil CD86. TRAF6 is associated with NF-κB activation
and production of IL-6 and IL-8, whereas TRAF2 is associated
with IκB-kinases. The binding site for TRAF2 but not TRAF6 is
required CD40-mediated antibody class switching (104–106).
Specific targeting of CD80 or CD86 by monoclonal antibodies
or soluble ligands could help to determine if additional IgG
subclasses exist in devils and to understand the potential role of
IL-6 and IL-8 in immune evasion by DFT cells.
In addition to binding to both CTLA-4 and CD28 in humans
and mice, CD80 binds to PD-L1 with a greater affinity than to
CD28, but less than affinity of CD80 for CTLA and PD-L1 for
PD-1 (107, 108). In humans, overexpression of CD80 blocks
PD-L1 expression by sequestering PD-L1 in the cytoplasm
while simultaneously providing costimulation (109). Additional
pleiotropic effects of CD80 include its ability to stimulate NK cells
through both CD28-dependent and -independent pathways
(110–112). As DFT1 cells are poorly immunogenic and do not
express MHC-I, the ability to stimulate NK cells using CD80
could provide immunotherapeutic potential.
Soluble CD80 can also effectively block PD-1:PD-L1 interactions and provide costimulation (113, 114). Interestingly, in
addition to the full-length devil CD80, we identified a devil CD80
splice variant that lacks a transmembrane domain (TMD) and
likely codes for soluble version of this key checkpoint molecule.
Humans are also known to express soluble CD80 and soluble
PD-L1, and high plasma levels of PD-L1 are associated with
poor prognosis in B cell lymphomas (115–117). The anti-PD-L1
monoclonal antibodies we have previously developed could be
used to screen devil plasma for soluble PD-L1 and possibly serve
as a prognostic test for DFT disease.

pro-apoptotic molecule (119–121). Altogether, devil 4-1BB has
key features that more closely resemble human 4-1BB, and thus
devil 4-1BB might stimulate T cell function but inhibit NK cell
function.
As expression of 4-1BB on T cells is largely dependent on activation state, combining agonistic anti-4-1BB immunotherapies
with stimulatory cytokines presents an opportunity for promoting immune memory. For instance, CD28- or IL-15-mediated
upregulation of 4-1BB combined with agonistic anti-4-1BB
monoclonal antibodies or recombinant 4-1BBL could promote
antigen-independent survival and expansion of memory CD8
T cells (122, 123); this could be critical for long-term memory
against repeated exposure to DFT cells in the wild. Also of
particular relevance to the DFT disease is that blockade of
4-1BB:4-1BBL pathways leads to prolonged allograft survival for
heart (124), skin (124), eye (125), and intestinal (126) tissues in
other species.

To Eat or Not to Eat: Phagocytic
Checkpoints
CD47

CD47 functions as an identifier of “self ” tissue and is expressed
on nearly all human and mouse cells. It has become known as
the “don’t eat me” signal due to its ability to inhibit phagocytosis
following ligation of SIRP-α (CD172a) on phagocytic cells
(i.e., APCs, macrophages) (127). Of particular relevance to trans
missible cancers, which are both allografts and cancer, CD47
appears to play a crucial role in transplant tolerance. The potent
inhibitory signaling capacity of CD47 was clearly demonstrated
in a xenotransplant model in which phagocytosis of pig cells
by human macrophages was abrogated by transfecting the pig
cells with human CD47 (128, 129). Several other studies have
confirmed the importance of the CD47:SIRP-α interaction in
graft and xenotransplant tolerance (129–132). Interestingly, the
intraspecies CD47:SIRP-α interaction and function seems to
be conserved in most species, but interspecies compatibility of
CD47:SIRP-α is low (133). This suggests that CD47:SIRP-α binding could be a barrier to interspecies transmission of tumors.
The closest extant relatives of devils, the Eastern quoll (Dasyurus
viverrinus) and spotted-tail quoll (Dasyurus maculatus), are
also a conservation priority, so understanding the role of CD47
in preventing interspecies transmission could prove useful for
conservation of quolls.
DFT1 and DFT2 are not xenotransplants in devils, but the
CD47:SIRP-α interaction could be a key mechanism of inhibiting phagocytosis and allo-responses against the DFT cells.
Interestingly, in rats and mice, CD47 has been implicated in
myelin phagocytosis through modulation of CD47:SIRP-α
interactions (134) This is an immune evasion pathway that may
have been exploited by DFT1, which originated from a Schwann
cell and expresses high levels of myelin (37). Despite the nearly
ubiquitous expression of CD47 by all cell types, expression levels
are highly variable and can be modulated by inflammation
(135, 136). High levels of CD47 found on many types of human
cancer, including leukemia (137–139), lymphoma (140), and several types of solid tumor cancers (141, 142) and are often associated

Devil 4-1BB Function Is Predicted to
Resemble Human 4-1BB Function

Despite the potential for enhanced immunotherapies targeting
the 4-1BB/L pathway, actual progress has been slow, in part due
to differences between mice and humans. 4-1BB costimulation
in both mice and humans leads to enhanced T cell-mediated
immunity, but the effects are contrasting in human and mouse
NK cells. In mice, 4-1BB stimulation leads to enhanced NK cell
effector mechanisms, but in humans 4-1BB signaling inhibits
NK effector activity and reverse signaling through 4-1BBL
on tumor cells can induce IL-10 and TNF-α (77, 118). This is
potentially mediated by a putative inhibitory motif 4-1BBLLYIFK in
the human cytoplasmic domain that resembles an ITIM domain
(76, 77). Interestingly, devils have a similar putative 4-1BBLPYFLK
inhibitory domain that includes the key tyrosine residue, but
opossum 4-1BB does not contain the putative inhibitory motif
(4-1BBLSFLLQ). Comparative testing of opossum and devil 4-1BB
should be able to determine the inhibitory capacity of these
motifs. Devil 4-1BB also contains conserved TRAF1/2-binding
sites that in humans are necessary for recruiting TRAF1 and
TRAF2 and inducing expression of pro-survival genes, including Bcl-2, Bcl-XL, and Bfl-1 and decreasing expression of Bim, a
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partial and complete allogenic hematopoietic cell transplantation in mice with mismatched MHC between donor and host
(155). This is of particular relevance to DFT, which in most
cases likely has mismatched MHC, so blockade of VISTA could
prove useful for breaking tolerance to DFT cells. In addition to
the role of VISTA in transplant tolerance, early studies suggest
that VISTA could play a more general role in immune escape by
tumor cells. Several groups have independently demonstrated
that VISTA-deficient mice have enhanced antitumor immunity compared to wild-type mice (156, 157). These effects are
independent of PD-1 but are amplified in VISTA/PD-1 double
knockout mice (158).

with poor prognosis. Importantly, blockade of CD47:SIRP-α
interactions stimulated enhanced antitumor responses in several
mouse models of human cancer (141, 143, 144), and trials of
anti-CD47 antagonistic monoclonal antibodies are underway
in humans. The MYC oncogene transcription factor binds to
the promotors of both CD47 and PD-L1 and expression of both
CD47 and PD-L1 can be downregulated by targeting MYC (145),
presenting an opportunity to simultaneously target both PD-L1
and CD47.
A drawback of the anti-CD47 monoclonal antibody treatment
is that CD47 blockade can lead to anemia due to rapid depletion
of red blood cells. However, this risk could potentially be minimized by injection of anti-CD47 mAbs or SIRP-α fusion proteins
directly into accessible DFTs (i.e., tumors in the mouth and face)
(146). In addition to facilitating cancer cell immune evasion,
CD47 also affects T cell and NK cell homeostasis (147, 148).
CD47 is suggested to facilitate longevity by reducing clearance by
phagocytes (135). Blockade of CD47 could thus decrease memory
cell longevity and increase turnover of T cells and NK cells and
could be detrimental to long-term DFT immunity in wild devils
that could be re-exposed to DFT.

TIM-3

Like VISTA, TIM-3 plays a role in phagocytosis of apoptotic cells
and T cell immunity [reviewed in Ref. (88)]. Ligation of TIM-3
by phosphatidylserine on apoptotic cells induces an “eat me”
signal (159–161). The interaction of TIM-3 with its coreceptors
has been associated with diverse functional outcomes, including
both inhibitory and stimulatory functions. TIM-3 also binds to
secreted and surface-expressed galectin-9 (GAL-9, LGALS9)
and negatively regulates Th1 immunity and IFN-γ production
(162, 163). As DFT1 cells do not naturally express MHC-I or
PD-L1 but upregulate both MHC-I and PD-L1 in response to
IFN-γ, the potential role of TIM-3 in IFN-γ production warrants
further investigation. TIM-3 and PD-1 are often coexpressed on
exhausted CD8+ T cells (164) in mice and exhausted TILs in mice
and humans (165–168).
In contrast to the inhibitory function of TIM-3 on adaptive
T cells, several types of innate immune cells can be activated by
TIM-3 ligation (169). Ligation of TIM-3 on mouse and human
DCs promotes secretion of inflammatory cytokines (169). TIM-3
is upregulated by TGF-β on tumor-associated macrophages
(TAMs) of the M2 phenotype and ligation of TIM-3 leads to
increased NF-κB and IL-6 production and is associated with
reduced survival in human hepatocellular carcinoma (170).
TIM-3 also binds to the pleiotropic alarmin HMGB1 and suppresses antitumor immunity via interfering with the ability of
HMGB1 to transport tumor-derived DNA to the endosomes
of DCs (171). As large DFTs often become ulcerated and/or
necrotic, it will be interesting to see if HMGB1 or other alarmins
are expressed.
In regard to receptor structure, TIM-3 is unique due to the
formation of both cis- and trans-heterodimers with carcinoembryonic antigen cell adhesion molecule 1. The cis heterodimerization is critical for stable surface expression of TIM-3 and its
inhibitory function (172, 173). Together, the conserved disulfide
bonds and ligand-binding amino acids, suggest that devil TIM-3
function might be similar to humans and mice. Several of the most
widely used cell lines in laboratory research, including Chinese
hamster ovary cells, Jurkat RMA-S human lymphoma cells, and
3T3 mouse fibroblast cells, express natural ligands that bind to
TIM-3 tetramers (89). This presents the opportunity for the use of
cross-reactive reagents for devils and other non-traditional study
species, but as a cautionary note, it also has the potential to cause
confusing results in attempts to understand checkpoint molecule
interactions.

V-Domain Ig Suppressor of T Cell Activation

In contrast to the “don’t eat me” signal from CD47 ligation,
VISTA can function as an “eat me” signal via intercellular
homophilic binding that affects clearance of apoptotic cells and
immune surveillance by macrophages and T cells (149, 150).
VISTA expression is upregulated in response to genotoxic stress
in a p53-dependent manner, and homophilic VISTA interactions
both in cis and trans among tumor cells, APCs, and T cells may
facilitate tumor cell escape from immune surveillance (149).
No polymorphisms in devil p53 have been reported (151), but
given the chromosomal rearrangements and greater than 17,000
somatic mutation reported in DFT1 cells (152, 153), it seems
probable that p53 would be at least occasionally activated in
DFT cells and could induce upregulation of tolerogenic VISTA
signaling.
The tolerogenic role of VISTA in humans and mice and the
strong conservation of VISTA across the nine species analyzed
here (only B7-H4 and CTLA-4 were more conserved) suggest that VISTA may play an important evolutionary role in
maintaining the balance between tolerance and immunity in
mammals. Despite high sequence identity, the ELM tool unexpectedly predicted a putative TRAF1/2 (VISTASIQE) binding site
in the ECD of devil VISTA. TRAF binding sites are most commonly found in TNF receptors, such as CD27, CD40, OX40,
and 4-1BB.
Interestingly, two independent research groups first identified VISTA, but each reported contrasting functional effects
of anti-VISTA monoclonal antibodies. One study reported
that mouse VISTA inhibited T cell proliferation and cytokine
production in vitro, that antagonistic anti-VISTA monoclonal
antibody treatment exacerbated experimental autoimmune
encephalomyelitis, and that VISTA overexpression on tumor
cells led to reduced antitumor immunity in mice (154). By
contrast, a single dose of agonistic anti-VISTA monoclonal
antibody completely abrogated graft-versus-host disease in a
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Paired Inhibitory and Stimulatory
Receptors

contain ITSMs: BTLA; 2B4 (CD244); Siglec7; Siglec9; SLAMF1
(CD150); Ly9 (SLAMF3); CD84 (SLAMF5); SLAMF6 (CD352);
and SLAMF7 (195, 196). Paired inhibitory and stimulatory receptors are hypothesized to have evolved in response to exploitation
of inhibitory receptors by pathogens. Thus, pathogen motifs
that utilize the inhibitory receptor will also trigger the stimulatory signal, so it is interesting that the three of the families that
contain ITSMs are also predicted to be paired-receptor families
(SIRP, CD200, Siglecs). The original ITSM was identified in
CD150 and was named “switch-motif ” due to its ability to switch
from recruitment of SHP-2 to SHIP in the presence of SH2D1A
(17, 197). This flexible switching aspect of the paired receptors
could be an additional evolved response to exploitation of inhibitory receptors by common pathogens.

CD47 binds to several coreceptors, including SIRP-γ, THSB1,
and THSB2, which induce either activation or inhibition signals
(174, 175). An additional SIRP-family protein, SIRP-β1, does not
bind to CD47 and no ligand for SIRP-β1 has been identified to
date in humans (176). The SIRP-family proteins are hypothesized
to be paired receptors that have evolved to reduce pathogen
exploitation of conserved motifs found in inhibitory receptors,
essentially a decoy target system that facilitates pathogen control.
Pathogens that trigger inhibitory signals via conserved motifs in
inhibitory receptors would thus also trigger activation signals
when exploiting the similar motifs in the activating receptor
(177, 178). Analysis of devil SIRP-α revealed two predicted cytoplasmic ITIM and one ITSM inhibitory domains, suggesting the
inhibitory capacity of the CD47:SIRP-α interaction is conserved
in devils and could be an immunotherapy target. The devil
SIRP-α ITSM was not detected in any other species, so empirical
testing will be needed to clarify the potential for targeting the
CD47:SIRP-α pathway in devils.
Like the SIRP-family proteins, members of the CD200R family
are hypothesized to have evolved as paired activating and inhibitory receptors. Specifically, herpesviruses, cytomegaloviruses,
pox viruses, and adenoviruses inhibit macrophage activation via
CD200 mimics that bind to CD200R-family members (179–181).
In recent years, CD200 has received greater interest as an inhibitory checkpoint molecule associated with antitumor immunity.
CD200 is expressed on a wide range of tumors, including lymphomas (182), myelomas (183), leukemias (184), and gliomas
(185), and CD200 expression is correlated with expression of
epithelial cancer stem cell markers on prostate, brain, breast, and
colon cancers (186, 187).
Expression of CD200 on tumor cells has been associated
with impaired NK cell function, increased frequencies of Tregs,
suppression of memory T cells, decreased CTL activity, and
induction of tolerance to allografts (184, 188, 189). Interestingly,
CD200 expression has also been associated with Th2-skewed
cytokine profiles and prolonged allograft survival (190–193).
The transplantable EMT6 mouse breast cancer line expresses
low levels of CD200 in vitro, but upregulates CD200 following
inoculation into immunocompetent mice (194); this is similar to
PD-L1, which is often expressed at low levels in vitro, but rapidly
upregulated in immune active environments. Given the ongoing
transmission of DFT for at least 20 years, immunohistochemical analysis of archived DFT tissue samples should determine
expression levels of CD200 in the tumor microenvironment, and
understanding this potential inhibitory pathway could help direct
vaccine-development efforts.
Like devil PD-1, devil CD200 and SIRP-α are predicted to
contain ITSM domains capable of regulating TCR signal transduction. ITSMs have been reported for both PD-1 and SIRP-α,
but to our knowledge this is the first report of an ITSM in CD200.
Interestingly, the CD200 ITSM was predicted only for devils and
not any of the other eight species analyzed here, although it is
possible that other isoforms of CD200 exist. There have only
been a limited number molecules that have been predicted to
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The Unexplored Function of ECD ITIMs
and ITSMs

The short cytoplasmic tail of CD200 and known soluble forms in
humans suggests that the primary inhibition through CD200 is
mediated via ligation of CD200Rs. However, as mentioned above
we identified a potential inhibitory ITSM in the extracellular
region of CD200NKTEYVVI. Interestingly, our analysis predicted
putative inhibitory motifs in the extracellular region of several
checkpoint molecules: devil CD47LKYHVV ITIM near the border of
the first extracellular and TMDs; devil SIRP-β1VSYNLI extracellular
ITIM; dog CD80VKYGDL extracellular ITIM; and human CD86IEYDGI
extracellular ITIM.
To our knowledge, the function of ITIMs and ITSMs has only
been explored in intracellular regions of checkpoint molecules.
However, despite most checkpoint molecules being considered
transmembrane proteins, the majority of checkpoint molecules
covered in this analysis are only surface expressed in particular
contexts. For instance, CTLA-4 protein can be detected in the
cytoplasm prior to T cell activation, but then is transiently moved
to the cell surface following activation. Trans-endocytosis of
ITIM-containing CD80 (dog) or CD86 (human) could allow the
ECD ITIMs to affect intracellular signaling. Also, CD80, CD86,
CD200, CD47, all of which were identified to contain extracellular
inhibitory domains, are part of multi-receptor or paired-receptor
interactions and the potential role of ECD ITIMs and ITSMs may
have been overlooked. This is potentially an understudied aspect
of molecular and cellular immunology that warrants further
investigation.

The Potential for LAG-3 As an Adjuvant

Although human LAG-3 has a higher affinity for MHC-II than
CD4, the inhibitory effects of LAG-3 in humans and mice
are thought to be mediated primarily via negative regulation
of TCR:CD3 signal transduction rather than competition
for MHC-II binding (198, 199). In addition to binding to
MHC-II, LAG-3 also binds to C-type lectin domain family
4 member G (CLEC4G, LSECTin) and galectin 3 (Gal-3,
LGALS3). In mice, Gal-3 expression can suppress CD8 antitumor responses and expansion of plasmacytoid DCs (200).
Tumor cell expression of Gal-3 has also been associated with
poor prognosis in non-small-cell lung cancer (201), Hodgkin
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lymphoma (202), and acute myeloid leukemia (203), but the
opposite effect has also been reported for breast (204) and
gastric (205) cancer.
Of particular interest for devils is the potential for LAG-3
to facilitate anti-DFT immunity. Immunization of mice with
LAG-3+ tumor cells, or irradiated tumor cells along with soluble
LAG-3-Ig resulted in tumor regression or reduced tumor growth
(206). In addition, soluble LAG-3-Ig binding to MHC-II reliably
induced DC maturation, which is indicated by upregulation of
MHC-II, costimulatory molecules CD40, CD80, CD83, CD86,
and IL-12 and TNF-α cytokines (207, 208). In allogenic bone
marrow transplant models, LAG-3 blockade abrogates CD8
T cell tolerance to tissue transplants (209), which suggests
that LAG-3 blockade could be a target for inducing CD8 T cell
responses to allogenic DFT cells. Additionally, because LAG-3
signaling is bidirectional, DFT expressed Gal-3 could inhibit
T and NK cell responses via direct Gal-3:LAG-3 interactions.
Finally, LAG-3 and PD-1 are coexpressed in exhausted T cells
in viral infection and on TILs, and blockade of both LAG-3 and
PD-1 has been demonstrated to have synergistic effects in mouse
models (33, 210–212). Altogether, there is a strong potential for
LAG-3 to stimulate anti-DFT immunity due to the potential for
overexpression of LAG-3 on tumor cells and/or administration
of soluble LAG-3-Ig to serve as an adjuvant, and to use monoclonal antibodies that block LAG-3 on T cells to reduce T cell
inhibition.

humans and mice, BTLA4, has not yet been identified in devils.
Multiple BTLAs have been identified in bony fish (Teleosts), but
have not been identified in amphibians or aves (24). Our search of
GenBank and Ensembl and also our de novo assembly of a transcriptome from devil PBMCs failed to identify a BTLA gene and
full coding sequence for the TIGIT gene in devils. Several TIGIT
coreceptors are present in the devil genome and three TIGIT
transcript variants reported in the opossum genome. Given that
TIGIT expression appears to be tightly regulated in humans and
mice (219), we believe it likely that a functional TIGIT gene will
eventually be detected in devils through targeted laboratory
methods (i.e., RACE PCR).

CONCLUSION
In addition to the highly conserved motifs in several molecules,
we documented strong conservation of cysteine residues for
intra- and intermolecular bonds. These remarkable similarities
suggest that immunotherapies that have revolutionized human
oncology might be translatable into immunotherapies for the DFT
disease. The wealth of data on checkpoint molecule expression
and function in humans should facilitate understanding of the
key immune evasion pathways employed by the DFTs and allow
development of vaccines that target these key pathways. However,
given the general paucity of reagents for non-traditional study
species, innovative new techniques may be needed to assess the
potential roles of the putative signaling motifs, and more generally to assess checkpoint molecule function in species other than
humans, mice, and rats.
Investigations into the function of checkpoint molecules
in devils, dogs, and hamsters may provide insight into the
transmissibility of these tumors and uncover potential immunotherapy targets relevant to both human and veterinary
medicine. Additionally, our analysis has spawned new questions about the role of inhibitory ITIM and ITSM motifs and
paired receptors that could be of highly relevant generally—not
only to human medicine. Further insight into the evolution
of the immune system might be gained by studying the role
of checkpoint molecules in natural disease systems, such as
white-nose syndrome in bats and chytridiomycosis in amphibians. Diversifying immunological studies into non-traditional
species may facilitate a broader understanding of key immune
defense pathways and elucidate general principles that are
unlikely to be found when studying only a small number of
model organisms.

Strong Conservation of B7-H4 Protein
across All Species

Despite more than a decade of searching, the identity of the
B7-H4 coreceptor remains unknown. Further complicating the
functional role of B7-H4 protein is that it is commonly expressed
in the cytoplasm and nucleus of cancer cells, and nuclear
localization of B7-H4 is associated with cell cycle progression
and proliferation of cancer cells (95). B7-H4 is upregulated to the
cell surface on T and B cells by several mitogens (213, 214) and
on monocytes, TAMs, and DCs in response to IL-6 and IL-10
(215, 216).
Despite the receptor for B7-H4 being unknown, the inhibitory
function of B7-H4 in regard to T cell responses and apoptosis
has been well-documented (213, 214, 217). Binding of B7-H4-Ig
to the putative coreceptor inhibits T cell activation, which can be
abrogated by monoclonal blockade of B7-H4 (213, 214). B7-H4
protein has been detected on breast, lung, ovarian, prostate,
renal cell, and uterine endometrioid cancer cells and is associated with decreased survival [reviewed in Ref. (20, 218)]. The
high sequence identity of B7-H4 between humans and devils
(87%) suggests that B7-H4 function might be similar in devils,
and thus could be used as a prognostic indicator for DFT in
addition to the potential for anti-B7-H4 monoclonal antibody
immunotherapy.
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